AUG 25, 2022 7:17 AM PDT

Could Next Season's Flu Shots Use mRNA Vaccines?

WRITTEN BY: Zoe Michaud

Traditional flu vaccines contain deactivated copies of the influenza virus. This deactivated virus allows your body to learn to recognize a protein called an antigen on the surface of the virus. Since the virus is deactivated, this learning process occurs without you getting sick. If a person who has been vaccinated against the flu is exposed to the influenza virus after being vaccinated, the body will quickly recognize the infection and fight the flu using antibodies. 

The creation of the traditional flu vaccine is a process that begins many months before the anticipated flu season. The U.S. Food and Drug Administration (FDA) makes an educated guess about which flu strains will be dominant in the upcoming flu season and includes them in the vaccine-manufacturing process. Since the dominant strain is impossible to predict with 100% accuracy, the resulting flu vaccine may be more or less effective depending on the year.

mRNA vaccines, which are generally quicker to develop and manufacture, work a little differently. mRNA vaccines provide the genetic material for your body to make the antigen protein directly. Just like a traditional flu vaccine, the body then creates antibodies in response to the antigen proteins. 

Recently, the biotechnology company Moderna announced that they began dosing participants with an mRNA influenza vaccine as part of a Phase 3 study of vaccine candidate mRNA-1010. The company expects to enroll 6,000 participants in total in this study. 

Stéphane Bancel, Chief Executive Officer of Moderna, says that “we believe our mRNA platform, with the flexibility and speed of our manufacturing process, is well-positioned to address the significant unmet need in seasonal flu.” 

Moderna also notes that in the future they could develop an mRNA vaccine that combines the seasonal flu with a SARS-CoV-2 booster. Since a phase 3 clinical trial typically lasts for 1 to 4 years, it’s possible that we could see mRNA flu vaccines within just a few flu seasons. 

Sources: Cedars-Sinai Medical Center, Healthline, Moderna

About the Author
Biology
Zoe (she/her) is a science writer and a scientist working in genomics. She received her B.S. from the University of Connecticut with a focus in Evolutionary Biology. At Labroots, she focuses on writing scientific content related to clinical research and diagnostics.
You May Also Like
SEP 23, 2022
Immunology
Successful Immunotherapy Trial Sends Lupus Into Remission
SEP 23, 2022
Successful Immunotherapy Trial Sends Lupus Into Remission
Immunotherapy is generally known as a treatment for cancer. In CAR T cell therapy, a patient's T cells can be isolat ...
SEP 27, 2022
Cardiology
Diet Changes Majorly Reduce Heart Risks
SEP 27, 2022
Diet Changes Majorly Reduce Heart Risks
The best lifestyle approach to reducing high blood pressure may be the DASH diet.
NOV 11, 2022
Cancer
Veterans and Burn Pit Exposure
NOV 11, 2022
Veterans and Burn Pit Exposure
Today we recognize the Veterans Day holiday in the United States.  Each year, on November 11, Americans commemorate ...
NOV 16, 2022
Genetics & Genomics
Genes That Diagnose Lyme Disease are Identified
NOV 16, 2022
Genes That Diagnose Lyme Disease are Identified
Lyme disease is caused by a bacterium that is transmitted by tick bites. The incidence of Lyme disease has been increasi ...
NOV 18, 2022
Neuroscience
Experiencing the Pain of Others
NOV 18, 2022
Experiencing the Pain of Others
Researchers noted an association between neural activity and the perceived intensity of pain that others feel, they publ ...
NOV 28, 2022
Clinical & Molecular DX
Study Indicates that Breast Cancer Recurrence Could be Predicted Using a MicroRNA Biomarker
NOV 28, 2022
Study Indicates that Breast Cancer Recurrence Could be Predicted Using a MicroRNA Biomarker
MicroRNAs are small (between just 21 and 23 nucleotides), non-coding RNA molecules. They are involved in the post-transc ...
Loading Comments...